Neal Shore, MD, FACS

Articles

The Benefits of Multidisciplinary Care in Prostate Cancer Management

January 12th 2024

Panel discusses how collaboration between specialties improves patient outcomes.

Key Takeaways on Evolving Bladder Cancer Treatment Landscape

December 21st 2023

The expert panel concludes its discussion by providing key takeaways on the evolving bladder cancer treatment landscape following ESMO 2023.

Approach to Collaborative Care in Bladder Cancer

December 21st 2023

The panel discusses the Large Urology Group Practice Association and provides insights on collaborative care approaches in bladder cancer.

Metastatic Prostate Cancer: Background and Patient Prognosis

December 20th 2023

An expert provides an overview of metastatic prostate cancer, including information on how it advances, patient prognosis, and what factors influence outcomes.

Optimizing Care of Patients With Advanced Prostate Cancer: Introduction

December 19th 2023

Brief background on prostate cancer and overview of the program.

Enfortumab Vedotin and the Role of ADCs in Bladder Cancer

December 15th 2023

Bladder cancer specialists discuss enfortumab vedotin and the role of antibody-drug conjugates in the treatment landscape.

Bladder Cancer: Highlights from ESMO 2023 and Ongoing Developments

December 15th 2023

The expert panel reviews highlights from ESMO 2023 and discusses ongoing developments in the treatment landscape for bladder cancer.

Bladder Cancer: Treatment Options and Managing Adverse Effects

December 7th 2023

Comprehensive insights on treatment considerations and managing immunotherapy-related adverse effects for patients with bladder cancer.

Monitoring Patients With NMIBC

December 7th 2023

The panel discusses strategies for monitoring patients with non–muscle invasive bladder cancer and the potential role of biomarkers.

Treatment Considerations and Role of Trimodal Therapy in Bladder Cancer

November 30th 2023

Expert perspectives on treatment options available for patients with bladder cancer and the role of trimodal therapy.

Overview of Non–Muscle Invasive Bladder Cancer (NMIBC)

November 30th 2023

A panel of experts on bladder cancer provide an overview of the stratification, natural history, and treatment of bladder cancer.

Dr Shore on the Rationale for the EMBARK Trial in Nonmetastatic Prostate Cancer

May 10th 2023

Neal Shore, MD, FACS, discusses the rationale for the phase 3 EMBARK trial investigating enzalutamide plus leuprolide in patients with nonmetastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence.

Dr. Shore on the Importance of Genetic Testing in Prostate Cancer

November 11th 2022

Neal Shore, MD, discusses the importance of incorporating genetic testing into treatment strategies for patients with prostate cancer.

Dr. Shore on Future Clinical Research Focuses in Prostate Cancer

October 14th 2022

Neal Shore MD, FACS, discusses future clinical research focuses in prostate cancer.

Dr. Shore on the Results of the ENACT Trial in Prostate Cancer

September 13th 2021

Neal D. Shore, MD, FACS, discusses the results of the randomized, open label, phase 2 ENACT trial in prostate cancer.

Latest in Myeloma, Prostate Cancer, and Lymphoma From ASCO 2021: Drs Neal Shore, Loretta Nastoupil, and Sandy Wong

June 9th 2021

OncLive sits down with Sandy Wong, MD; Neal Shore, MD; and Loretta Nastoupil, MD, to share the the insight on data in multiple myeloma, prostate cancer, and non-Hodgkin lymphoma at the 2021 ASCO Annual Meeting.

Dr. Shore on Unmet Needs in Nonmetastatic CRPC

October 23rd 2020

Neal D. Shore, MD, FACS, discusses unmet needs in nonmetastatic castration-resistant prostate cancer.

Dr. Shore on the Design of the HERO Trial With Relugolix in Advanced Prostate Cancer

October 19th 2020

Neal D. Shore, MD, FACS, discusses the design of the phase 3 HERO trial in patients with advanced prostate cancer.

Dr. Shore on the HERO Trial With Relugolix in Advanced Prostate Cancer

October 15th 2020

Neal D. Shore, MD, FACS, discusses the results from the phase 3 HERO trial with relugolix in men with advanced prostate cancer.

Dr. Shore on Benefits of Immunotherapy INO-5150 in Recurrent Prostate Cancer

July 8th 2020

Neal D. Shore, MD, FACS, discusses the potential benefits of the immunotherapy INO-5150 for patients with biochemically recurrent prostate cancer.